FCGRT and tropical spastic paraparesis: Efgartigimod, by targeting immune responses through FcRn inhibition, offers a unique mechanism of action that, when paired with corticosteroids, could effectively modulate the chronic inflammation and neuroimmune damage associated with HAM/TSP.